OBJECTIVES: In order to provide new source for discovering new lead compounds of drugs and other products, the diversity and some bioactivities of culturable actinobacteria in animal feces were studied. METHODS: Five animals' fecal samples were collected from Yunnan Wild Animal Park. The pure cultures of actinobacteria were isolated from these samples by using 5 different media. The 16S rRNA gene sequences of 119 selected strains were determined; the phylogenetic analysis was carried out; and antimicrobial and anti-tumor activities were determined by using agar diffusion method, tumor cell lines k562and HL60 respectively. RESULTS: In total 20 genera of actinobacteria from the 5 animals' feces were identified. Many strains inhibited Bacillus subtilis, Staphylococcus lentus, Mycobacterium tuberculosis, Candida albicans and Aspergillus niger. Some strains presented antitumor activities. Some known secondary metabolites and Sannastatin, a novel macrolactam polyketide glycoside with bioactivities, were isolated and identified. CONCLUSION: Fecal actinobacteria are a new potential source for discovering drug lead and other industry products.
OBJECTIVES: In order to provide new source for discovering new lead compounds of drugs and other products, the diversity and some bioactivities of culturable actinobacteria in animal feces were studied. METHODS: Five animals' fecal samples were collected from Yunnan Wild Animal Park. The pure cultures of actinobacteria were isolated from these samples by using 5 different media. The 16S rRNA gene sequences of 119 selected strains were determined; the phylogenetic analysis was carried out; and antimicrobial and anti-tumor activities were determined by using agar diffusion method, tumor cell lines k562and HL60 respectively. RESULTS: In total 20 genera of actinobacteria from the 5 animals' feces were identified. Many strains inhibited Bacillus subtilis, Staphylococcus lentus, Mycobacterium tuberculosis, Candida albicans and Aspergillus niger. Some strains presented antitumor activities. Some known secondary metabolites and Sannastatin, a novel macrolactam polyketide glycoside with bioactivities, were isolated and identified. CONCLUSION: Fecal actinobacteria are a new potential source for discovering drug lead and other industry products.